A Multicenter Study on the Challenges and Real-World Utilization of Immune Checkpoint Inhibitors in Resource-Constrained Settings: Insights and Implications from India.

ABSTRACT: Using immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment, but access and affordability remain significant challenges, particularly in resource-constrained settings. This multicenter study evaluated the utilization, outcomes, and challenges associated with ICIs in India. Data from multiple centers involving patients treated between January 2018 and December 2021 were retrospectively collected. Patient demographics, treatment indications, biomarker testing, financial coverage, toxicity, treatment discontinuation, clinical benefit, progression-free survival (PFS), and overall survival (OS) were analyzed. Ninety-one patients were analyzed; lung cancer (39.6%) and renal cancer (11%) were the main indications for ICI use. Programmed death ligand 1 expression was tested in 40

SUBMITTER: Philips AO 

PROVIDER: S-EPMC11925610 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature